Enzolytics, Inc. (ENZC)

Market Cap	1.45M -57.1%
Revenue (ttm)	46.59K +26.0%
Net Income	-1.03M
EPS	-4.76
Shares Out	4.83B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,600
Average Volume	14,896,678
Open	0.0003
Previous Close	0.0003
Day's Range	0.0003 - 0.0003
52-Week Range	0.0000 - 0.0011
Beta	-0.18
RSI	37.23
Earnings Date	n/a

About Enzolytics

Enzolytics Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company’s proprietary cell line produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is b...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Steven Sharabura
• Employees: 3
• Stock Exchange: OTCMKTS
• Ticker Symbol: ENZC

Financial Performance

In 2011, Enzolytics's revenue was $52,807, an increase of 42.85% compared to the previous year's $36,968. Losses were -$882,928, -88.25% less than in 2010.